Atea Pharmaceuticals, Inc. (AVIR) vs Neurogene Inc. (NGNE)
A side-by-side comparison of Atea Pharmaceuticals, Inc. and Neurogene Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVIR
Atea Pharmaceuticals, Inc.
$5.12HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NGNE
Neurogene Inc.
$25.79HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — AVIR vs NGNE
growth of $100 · dividends reinvested · last 6yAVIR -83.1% (-25.6%/yr)NGNE -87.4% (-29.2%/yr)AVIR compounded faster over this window
AVIR NGNE
AVIR vs NGNE: by the numbers
- •AVIR is the larger company ($409M vs $408M market cap).
Metrics side by side
Valuation
| Metric | AVIR | NGNE |
|---|---|---|
| P/B ratio | 2.01 | 1.88 |
Profitability
| Metric | AVIR | NGNE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -80.96% | -51.17% |
| ROIC | -89.93% | -54.45% |
Growth (annualized)
| Metric | AVIR | NGNE |
|---|---|---|
| Total return CAGR (5Y) | -34.44% | -27.73% |
Frequently asked
- How have AVIR and NGNE total returns compared?
- Over the past 5 years, AVIR delivered -34.44% and NGNE delivered -27.73% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.